Document is current

Article History

First Online: 4 June 2019

Compliance with Ethical Standards

:

: S.M. Larson reports receiving commercial research grants from Genentech, Inc., Wilex AG, Telix Pharmaceuticals Ltd., and Regeneron Pharmaceuticals Inc., has ownership interest (including stock, patents, <i>etc.</i>) in Imaginab, Inc., Samus Therapeutics Inc., Elucida Oncology Inc., Voreyda Theranostics Inc., and YMABS Therapeutic Inc., is a consultant/advisory board member for Cynvec LLC, Eli Lilly, Prescient Therapeutics Limited, Advanced Therapeutic Partners, Gerson Lehman Group, Progenics, and Janssen Pharmaceuticals Inc., and has received other remuneration from Fonde de Research Sante, Quebec. All are outside the scope of current work. G. W. Pasternak. reports personal fees and/or other fees from Novartis, Collegium, Nektar, Confo, Endo, outside the current work; He is a co-founder of Sparionbio. S. Majumdar reports other interests from Palion Therapeutics, outside the submitted work; He is a co-founder of Sparionbio. N Pillarsetty reports that he is an inventor and owner of issued patents both currently unlicensed and licensed by MSK to Samus Therapeutics, Inc., which are outside the scope of current work.

: All applicable institutional and/or national guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.